Loading...
XNAS
ASND
Market cap8.54bUSD
Apr 04, Last price  
142.67USD
1D
-4.94%
1Q
1.62%
Jan 2017
604.89%
IPO
613.35%
Name

Ascendis Pharma A/S

Chart & Performance

D1W1MN
P/E
—
P/S
21.42
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.28%
Rev. gr., 5y
93.59%
Revenues
364m
+36.34%
15,583,00020,408,00013,983,0008,118,0004,606,0001,530,00010,581,00013,375,0006,953,0007,778,00051,174,000266,718,000363,641,000
Net income
-378m
L-21.47%
1,250,0004,079,000-9,658,000-32,922,000-68,505,000-123,897,000-130,097,000-218,016,000-418,955,000-383,577,000-583,194,000-481,447,000-378,084,000
CFO
-306m
L-34.48%
-652,0006,310,000-18,403,000-43,466,000-60,179,000-95,099,000-138,802,000-175,936,000-271,548,000-417,649,000-495,699,000-467,361,000-306,197,000
Earnings
Apr 30, 2025

Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
URL
https://ascendispharma.dk/
IPO date
Jan 28, 2015
Employees
797
Domiciled in
DK
Incorporated in
DK

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
363,641
36.34%
266,718
421.20%
51,174
557.93%
Cost of revenue
635,807
457,849
391,761
Unusual Expense (Income)
NOPBT
(272,166)
(191,131)
(340,587)
NOPBT Margin
Operating Taxes
4,843
7,303
5,377
Tax Rate
NOPAT
(277,009)
(198,434)
(345,964)
Net income
(378,084)
-21.47%
(481,447)
-17.45%
(583,194)
52.04%
Dividends
Dividend yield
Proceeds from repurchase of equity
309,913
8,263
(100,245)
BB yield
-3.93%
-0.12%
1.46%
Debt
Debt current
491,536
25,400
25,421
Long-term debt
365,080
717,658
592,147
Deferred revenue
5,000
14,213
Other long-term liabilities
155,075
157,950
Net debt
283,498
337,933
(148,311)
Cash flow
Cash from operating activities
(306,197)
(467,361)
(495,699)
CAPEX
(1,427)
(2,442)
(14,489)
Cash from investing activities
6,876
286,474
61,732
Cash from financing activities
443,929
134,292
396,773
FCF
(217,665)
(271,444)
(360,715)
Balance
Cash
559,543
399,439
735,455
Long term investments
13,575
5,686
30,424
Excess cash
554,936
391,789
763,320
Stockholders' equity
8,149
(2,422,792)
(1,591,929)
Invested Capital
747,761
3,076,435
2,530,327
ROIC
ROCE
EV
Common stock shares outstanding
57,346
56,287
56,072
Price
137.67
9.31%
125.95
3.13%
122.13
-9.22%
Market cap
7,894,771
11.36%
7,089,355
3.52%
6,848,048
-7.06%
EV
8,178,269
7,427,288
6,699,737
EBITDA
(254,452)
(172,220)
(322,629)
EV/EBITDA
Interest
65,504
44,065
50,487
Interest/NOPBT